The failure of an ICD to provide the necessary energy to the heart can result in serious injury or death. Thousands of Americans rely on these devices to literally keep them alive. Understandably, the frequency of recalls for ICDs and their components has been a source of much concern for heart patients and their physicians.
In June 2005, Guidant Corp. issued a series of recalls for many of their implantable pacemaker models. Throughout 2005 and 2006 Guidant recalled 22 different models:
Contak Renewal
Contak Renewal 2
Contak Renewal 3
Contak Renewal 3 AVT
Contak Renewal 4
Contak Renewal 4 AVT
Contak TR
Discovery
Discovery II
Insignia
Intelis II
Meridian
Nexus
Pulsar
Pulsar Max II
Renewal 3 AVT
Renewal 4 AVT
Renewal RF
Ventak Prizm 2 DR
Ventak Prizm AVT
Virtus Plus II
Vitality AVT
Guidant wasn't the only ICD manufacturer that had problems with their defibrillators. On February 3, 2005, Medtronic announced the recall of several models of ICDs because of battery problems which could cause them to fail. The recall involved Medtronic's Marquis line of ICDs, which included the following models:
Micro Jewel II Model 7223Cx
GEM DR Model 7271 ICDs
7230 Marquis VR
7274 Marquis DR
7232 Maximo VR
7278 Maximo DR
7277 InSync Marquis
7289 InSync II Marquis
7279 InSync III Marquis
In December 2007, Medtronic Corp announced that it agreed to settle 2,682 legal cases related to these recalled defibrillators for $114 million. $95.6 million plus $18.5 million The settlement came after Medtronic's attempt to have the lawsuits dismissed failed in November 2006, when a U.S. district court denied its request.
On October 15, 2007 Medtronic Corp recalled its Sprint Fidelis defibrillator leads because they can fracture and cause an ICD to issue unnecessary shocks or not provide needed shocks. A defibrillator lead connects an ICD to the heart, if a lead fractures it can send misinformation the ICD and cause serious complications. The recall involves the following Medtronic Sprint Fidelis models:
Sprint Fidelis 6930
Sprint Fidelis 6931
Sprint Fidelis 6948
Sprint Fidelis 6949
Medtronic has said that most patients will not need to have their leads replaced. The company believes that reprogramming devices for most patients will alleviate the increased risk posed by defective leads. However, this "solution" is not sitting well with many patients with recalled leads; these patients would prefer undergoing lead replacement surgery to have peace of mind.
The ICD market is already huge and quickly growing. In fact the market is so lucrative that there was a bidding war for Guidant Corp. even after the company recalled thousands of their devices. Johnson & Johnson and Boston Scientific were undeterred by the potential fallout over the recalls and both offered aggressive bids for the company. Boston Scientific finally outbid Johnson & Johnson and purchased the company for $25 billion dollars.